

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7393068

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
RK PHARMA SOLUTIONS LLC	06/16/2022

RECEIVING PARTY DATA

Name:	RK PHARMA INC
Street Address:	401 NORTH MIDDLETOWN ROAD, BUILDING 215/215A
City:	PEARL RIVER
State/Country:	NEW YORK
Postal Code:	10965

PROPERTY NUMBERS Total: 22

Property Type	Number
Application Number:	16690696
Application Number:	16804177
Application Number:	16898794
Application Number:	16899903
Application Number:	16893869
Application Number:	16910560
Application Number:	17354373
Application Number:	17355876
Application Number:	17020983
Application Number:	17023544
Application Number:	17034030
Application Number:	17075736
Application Number:	17075734
Application Number:	17079554
Application Number:	17124668
Application Number:	17174286
Application Number:	63230109
Application Number:	63231822
Application Number:	63045054
Application Number:	63045223

PATENT

Property Type	Number
Application Number:	17394832
Application Number:	63043865

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3473380059

Email: ap@lgtrademark.com

Correspondent Name: ANTONIO PAPAGEORGIOU

Address Line 1: 230 PARK AVENUE, 4TH FLOOR WEST

Address Line 2: LOMBARD & GELIEBTER LLP

Address Line 4: NEW YORK, NEW YORK 10169

NAME OF SUBMITTER:	ANTONIO PAPAGEORGIOU
SIGNATURE:	/Antonio Papageorgiou/
DATE SIGNED:	06/21/2022

Total Attachments: 3

source=2022_PATENT ASSIGNMENT _SIGNED#page1.tif

source=2022_PATENT ASSIGNMENT _SIGNED#page2.tif

source=2022_PATENT ASSIGNMENT _SIGNED#page3.tif

PATENT ASSIGNMENT

This Patent Assignment ("Agreement"), dated as of June 16th, 2022 (the "Effective Date"), is by and between RK Pharma Solutions LLC, a Limited Liability Company registered under the laws of New Jersey, having a place of business at 15 Corporate Place South Piscataway, New Jersey 08854 ("ASSIGNOR"), and RK Pharma Inc., a Corporation registered under the laws of Delaware, having a principle place of business at 401 North Middletown Road, Building 215/215A, Pearl River, NY 10965 ("ASSIGNEE") (collectively, the "Parties," or each, individually, a "Party").

WHEREAS, ASSIGNOR owns all right, title, and interest in and has the right to assign to ASSIGNEE the U.S. patents and patent applications listed in Schedule A ("Assigned Patents");

WHEREAS, ASSIGNOR wishes to assign to ASSIGNEE the Assigned Patents along with any and all rights associated therewith; and

NOW THEREFORE, for and in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

ASSIGNMENT

ASSIGNOR hereby assigns and transfers to ASSIGNEE the entire right, title, and interest in and to the Assigned Patents, together with the inventions described therein, and any extensions, reissues, substitutes, divisional, renewals, continuations, continuations-in-part, patent-filings within priority chains thereof, and patent filings claiming priority to patent filings in such priority chains, whether US or foreign, the same to be held and enjoyed by ASSIGNEE for its own use and enjoyment, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this Assignment had not been made.

ASSIGNOR agrees to perform, upon ASSIGNEE'S request and at ASSIGNEE'S expense, all acts reasonably serving to assure that the Assigned Patents and the inventions and discoveries therein, the patent applications and the patents, shall be held and enjoyed by ASSIGNEE as fully and entirely as the same could have been held and enjoyed by ASSIGNOR, its legal representatives, and assigns if this Assignment had not been made, and particularly to execute and deliver to ASSIGNEE all documents as may be requested by ASSIGNEE, to communicate to ASSIGNEE all facts known to ASSIGNOR relating to said inventions and discoveries or the history thereof, to furnish ASSIGNEE with any and all documents in the control of ASSIGNOR, its legal representatives, or assigns which may be useful for establishing the facts relating to, *inter alia*, conception, disclosures, and reduction to practice of said inventions and discoveries, and to testify as to the same in any proceeding or litigation.

This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. A signed


copy of this Agreement delivered by facsimile, e-mail, or other means of electronic transmission (to which a signed PDF copy is attached) will be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

This Agreement constitutes the entire agreement between the Parties as to the subject matter hereof, and all prior negotiations, representations, agreements, and understandings are merged into, extinguished by, and completely superseded by it. This Agreement may be modified or amended only by a writing executed by authorized officers of each of the parties.

If any provision of this Agreement is held to be unenforceable for any reason, it shall be adjusted rather than voided, if possible, in order to achieve the intent of the Parties to the extent possible. In any event, all other provisions of this Agreement shall be deemed valid and enforceable to the full extent possible.

IN WITNESS WHEREOF, ASSIGNOR and ASSIGNEE have caused this instrument to be executed on the date hereafter indicated.

Date: 16th June 2022

By: 

RK Pharma Solutions LLC

Date: 16th June 2022

By: 

RK Pharma Inc.

Schedule A

App. Serial No.	Title	Filing Date	Patent No.
16/690,696	Storage-Stable Ready-To-Use Injectable Formulations of Thiotepea	11/21/2019	11260065
16/804,177	Storage-Stable Ready-To-Use Injectable Formulations of Fosaprepitant Dimeglumine	02/28/2020	
16/898,794	Process For the Preparation of Eribulin Mesylate Intermediate	06/11/2020	
16/899,903	Process For the Preparation of Safinamide Mesylate Intermediate	06/12/2020	
16/893,869	Stable Pharmaceutical Composition of Selexipag	06/05/2020	
16/910,560	Process For the Preparation of Hydroxocobalamin Hydrochloride	06/24/2020	
17/354,373	Stable Acyclovir Sodium Parenteral Formulation	06/22/2021	
17/355,876	Ready To Use Injectable Formulations of Micafungin Sodium	06/23/2021	
17/020,983	Process For the Preparation of Degarelix Acetate and Degarelix Acetate-Mannitol Premix	09/15/2020	
17/023,544	Process For the Purification of Methylene Blue	09/17/2020	
17/034,030	Process For the Preparation of Ferric Citrate	09/28/2020	
17/075,736	Storage-Stable Ready-To-Use Injectable Formulations of Trabectedin	10/21/2020	
17/075,734	Storage-Stable Ready-To-Use Formulations of Tigecycline	10/21/2020	
17/079,554	Novel Polymorphic Form of Ferric Maltol	10/26/2020	
17/124,668	Ready To Use Injectable Formulations of Melphalan and Processes For Preparation Thereof	12/17/2020	
17/174,286	Purification Process of Ferric Carboxymaltose	02/11/2021	
63/230,109	Compositions Of Ferric Maltol for Oral Administration	08/06/2021	
63/231,822	Ready To Use Sterile Composition of Cetorelix Acetate	08/11/2021	
63/045,054	Ready To Use Injectable Formulations of Micafungin Sodium	06/27/2020	
63/045,223	Ready To Use Injectable Formulations of Micafungin Sodium	06/29/2020	
17/394,832	Storage-Stable Ready-To-Use Injectable Formulations of Trabectedin	08/05/2021	
63/043,865	Stable Acyclovir Sodium Parenteral Formulation	06/25/2020	

PATENT

RECORDED: 06/21/2022

REEL: 060263 FRAME: 0410